KR102073490B1 - Tablet-typed portable handy food substitue and preparation method thereof - Google Patents

Abstract

The present invention is to provide a new convenience processed food consisting of detoxification soup, substitute tablet, and portable convenience meal replacement with easy digestion and excellent preference. The new convenience processed food is prepared by processing the former which is processed products of grains and soybeans and the latter which is a mixture of shellfish, fruits and vegetables in a specific mixing ratio. According to the present invention, the new convenience processed food is useful by ensuring excellent effects of preventing and ameliorating metabolic disease.

Description

Portable convenient food substitue and preparation method

The present invention relates to a portable quick meal substitutes and a method for manufacturing the same, and relates to an adult one-person set meal consisting of a tablet-type substitute and a complex nutritional broth, which are useful for improving and preventing metabolic diseases in the human body.

Substitute meals are complete or semi-cooked foods, which are eaten instead of dinner, mid-night, and dinner. Instant bibimbap, instant porridge, etc. are commercially available. In the West, hamburgers and oatmeal are developed and marketed. However, these products are limited to eating by reheating in an oven or microwave oven and must be eaten at home, in a restaurant or in a shop.

On the other hand, raw foods or foods that have not been cooked or processed for diet have been developed by selecting various food materials. However, side effects such as indigestion or yo-yo occur are occurring sporadically. While these products are in development, these products are not popular because of their palatability.

Meanwhile, modern man's diet has become westernized in the process of industrialization and lack of exercise has resulted in a rapid increase in obesity, and eventually obesity has been the cause of hyperlipidemia, hypertension, cardiovascular disease, diabetes and various other cancers. The prevention or amelioration and treatment of metabolic diseases such as lipid-related obesity, diabetes and hypertension in the human body has become a major challenge in modern preventive medicine.

The mechanism of inducing chronic respiration caused by obesity is that the excess energy supply exceeds the accumulation limit of fat tissue, which is an energy store, and is accumulated in the triglyceride state in the organs in the non-fat tissue such as liver, muscle, pancreas and heart, and the free fatty acid in the blood is increased. Apoptosis and inflammation, fatty acid synthesis, decreased fatty acid oxidation rate, increased insulin resistance in muscle and liver, decreased insulin production in the pancreas and β cell death, heart failure in the heart, Myocardial infarction and non-alcholic fatty liver (NAFLD) in the liver are induced, and furthermore, the symptoms of insulin-resistant diabetes and metabolic syndrome that suppress fat accumulation through fatty acid synthesis inhibition and fatty acid increase are indicated.

The cause of obesity is a deficiency of the hormone leptin (leptin) secreted by the brain is known to occur due to overgrowth of fat cells. The deficiency of leptin hormone is reduced by animal cholesterol accumulated in the body due to weakening of metabolism in vivo due to overeating and aging, except for genetic causes. As a result, obesity is a phenomenon in which the consumed heat energy is consumed and the remaining portion is converted into adipocytes and accumulated in the subcutaneous tissue and the abdominal cortex in the body. At this time, because the size of fat cells is limited, excess heat energy is rapidly increased in order to store excessive heat energy, and thus, new fat cells continue to differentiate and grow, and these fat cells are differentiated from pro-adipocytes. They are organically differentiated from stem cells, and in the process of differentiating and growing stem cells from adipocytes, bioregulators such as hormone growth factors and cytokines are involved.

In this regard, anti-obesity drugs are being released on the market to temporarily eliminate obesity, such as Zenical (Korean algae), diazolidinediones (TZDs), and sibutramine. Xenical and cibutramine interfere with fat absorption, inhibit serotonin reuptake at the synapse, causing satiety, and thiazolidinedione inhibits glucose production, which is known to have an anti-obesity function. Side effects such as hepatic and renal failure have been reported.

Herbal extracts for the prevention and treatment of obesity and lipid-related metabolic diseases that have no side effects of the anti-obesity agents, reduce fat cells and inhibit triglyceride formation have been developed and researched. The metabolic disease prevention and treatment composition containing the extract of bark of organic solvents of Diplolocapitusculus plant is 10-1458062 and the composition for the prevention and treatment of lipid-related metabolic disease containing ultrasonic and hot water extract of ginseng is 10- 15015055, respectively.

In addition, a food composition for improving hyperlipidemia and obesity containing Bell mimosa (Dichrostachys glomerata) fruit extract and Wild mango (Irvingia gabonensis) seed extract is 10-1872456, and an anti-diabetic food composition containing barley and lettuce extract is 10-1859899, and the composition for the prevention of obesity and hyperlipidemia containing red bean fermented extract and isoflavones and L-carnitine as an active ingredient is disclosed in Korea Patent Application Publication No. 10-2012-37145, Pear extract and Bokryeong extract Obesity prevention and improvement functional food composition to the Republic of Korea Patent Publication No. 10-2015-29853, and anti-obesity composition containing a mixture of red ginseng extract, ivory tea extract and vulcanized powder are disclosed in Patent Registration No. 10-815200 It is.

The treatment of metabolic diseases such as lipid-related obesity and diabetic hypertension has rapidly increased to the market of obesity drugs due to the rapid increase in the obesity population, and the US Food and Drug Administration (FDA) is an obesity treatment drug that can be used for more than three months. (sibutramine), licensed to Ullistart in 1999, and Rimonabant was licensed for use in 2006 in the UK and other countries in Europe, but it was withdrawn from the market in 2009 due to mental side effects such as suicide. In 2010, due to the controversy for cardiovascular managers, the market was discontinued. To date, anti-obesity drugs are in recession, and the development of natural foods is urgently needed. (James wp et al., N. Engl. J. Med. 363: 905-917, 2010)

On the other hand, diabetes is a disease characterized by hyperglycemia due to absolute or relative deficiency of insulin and a decrease in insulin function in tissues and accompanying metabolic disorders, and it is steadily increasing along with the obese population due to inadequate diet. Diabetes is distinguished from Type 2 Diabetes Mellitus, in which insulin resistance is the main pathological symptom, unlike Type 1 Diabetes Mellitus, which is characterized by an absolute lack of insulin. It is closely related to lifestyle, such as form, obesity, lack of exercise, and stress.

Until now, sulfonylurea drugs that increase insulin secretion, pioglitazone and rosiglitazone that improve insulin action have been developed and used. In addition, Metformin drugs that reduce glycemic synthesis in the liver and post-prandial meals by preventing carbohydrate digestion Acarbose-based drugs that suppress blood sugar rise are used. However, the drug-formed Metformin-based drugs have reported side effects such as loss of appetite, bloating, vomiting, and diarrhea and rarely lactic acidosis in 20-30% of patients taking the drug. Such a phenomenon is urgently needed for the prevention and improvement of natural food-oriented diabetes, which is effective for the treatment of diabetes, and the research and development of treatment methods, when a natural regimen is required in the same way as a regular meal.

The body's blood cholesterol is also a cause of adult disease such as obesity, hyperlipidemia, thrombosis, high blood pressure arteriosclerosis, cerebral infarction or myocardial infarction. Along with quantitative increase in lipid protein components such as cholesterol and cholesterol, 3-hydroxy-3-methylglutaryl cofactor (HMG-) inhibits cholesterol biosynthesis as a drug for the treatment and prevention of the disease caused by the accumulation of cholesterol in the blood. Valonic acid inhibitor mevastatin from CoA) is used, which has a mechanism of inhibiting HMG-CoA reductase and other drugs such as bile acid adsorbents, and cholesterol lowering agents such as nicotinic acid, cholestywamin, clobibrate, neo Drugs such as mycin, tryparanol, D-tyrosine and estrogen hormones are being used.

As mentioned above, the master of adult disease is an excessive intake of fatty foods, and the excess of calories increases the lipid content in the body, causing circulatory disease, leading to an increase in blood cholesterol, hyperlipdemia and atherosclerosis (arteriosclaerosis). Has been reported to cause pancreatitis and pancreatic cancer. Cholestyramine (cholestyramine), which inhibits the resorption of bile acids in the intestine, lovastatin, which inhibits the synthesis of cholesterol, and gemfibrozil, which reduces the concentration of triglycerides in the blood Although side effects of liver and cardiac depression have been reported, substances having few such side effects have recently been disclosed (Patent Publication 10-2002-23429, Patent Publication 10-362940, Patent Publication 10-2002-95553, Patent Registration 10-). 291144, Registered Patent 10-291140 and Diers Reproductive Registered Patent 10-529844 derived from natural products, etc.)

Hypertension is a cardiovascular disease that affects 15-20% of adults worldwide and is reported to be caused by a combination of race, genetic, salt intake, insulin resistance, excessive drinking and aging, and plays an important role in blood pressure elevation. The responsible factor is known as the Renin-Angiotensin system (RAS), and its physiological activity is the renin-Angiotensin system activated by the blood flow, sodium reduction, and sympathetic nervous system activity in the kidneys, and Lenin converts Angiotensin to Angiotensin I. It is decomposed and converted into angiotensin II, which acts as a vasoconstrictor by angiotensin I-converting enzyme (ACE), and has a mechanism of reabsorption of sodium ions, increased release of K ions, and increased blood flow. It is.

Until now ramipril (ramipril), captopril (captopril), enarail (enarail), risinopril (risinopril), fosinoril (fosinoril) has been developed as an ACE inhibitor drug and these compounds are used in the pharmaceutical administration method As a result, the stability (stability) is lowered and acts on other cells, causing side effects such as loose whole body, vomiting, coughing, headache, anorexia or celiac abnormalities. (Lim SD et al., Korean J. Food Sco., Ani. Resour, 28 (5): 587-595, 2008) Accordingly, the development of ACE inhibitors derived from natural substances without side effects is one of the urgent tasks. (Korean Patent Registration 10-1275766, Korean Patent Publication 10-2012-92735, Korean Patent Registration 10-1819606, Korean Patent Registration 10-1154044, Korean Patent Publication 10-2011-121239, 10-2011-29893, Korean Patent Registration 10 -1663550, Korean Patent No. 10-971874, Korean Patent No. 10-146633 and the like).

However, the above patents are technologies for extracting and using natural medicines or natural herb plants or organic substances derived from foods with water-soluble organic solvents, which are effective for short-term prescriptions, that is, for prevention or treatment purposes, and are specific to humans. Therefore, there is a disadvantage that the effect is not constant. Therefore, in recent years, roasted or enzyme-treated meal substitutes having long-term preventive and improved functionalities have been studied, and Korean Patent Registration 10-1266329, 10-1841738, 10-0529844, 10-1866468 are known.

Therefore, in view of the above points, the present invention is characterized in that it is completed by long-term research and development using only pure grains without roasting or steaming process or fermentation process or enzyme treatment process or sugar treatment, and the object of the present invention is known so far. It is to provide a balanced diet for the proper energy metabolism by calculating enough calories (Kcal) necessary for the human body to be managed for one day.

Another object of the present invention is to provide a portable easy-to-use formula that can supply sufficient calories for daily adult life.

Still another object of the present invention is to provide a method for producing a dietary food which is required to prevent and improve metabolic diseases such as hyperlipidemia, hypertension, diabetes, obesity, or to treat already-affected patients by selecting foods that meet the above objectives. .

The above object of the present invention comprises the steps of: (a) selecting the most preferred cereals of 7 kinds of cereals and 6 kinds of soybeans in order to maintain a balanced diet in which the human body can operate; (b) increasing the thirteen kinds of ingredients obtained in the above step after washing with water; (c) drying each food ingredient increase obtained in the above step to a water content of 10 to 15%; (d) preparing the dried food ingredients into granules with a granulator and then redrying the dried foods with a water content of 10 to 13%; (e) The dried product obtained in the above step is formulated into granules, and then spun with a tableting machine and weighs 70 g corresponding to one adult 450-500 kcal calories per adult.

The tablets of the present invention prepared through the above steps have a calorie of 450 to 500 kcal, and grains suitable for providing the purpose of the present invention and 1350 to 1500 kcal calories and three times a day for adults are provided with glutinous rice and waxy rice. , 7 kinds of millet rice, Seosuk rice, waxy rice, whole wheat rice, oat rice, and two kinds of beans are Seomoktae (ratsui bean), seotaetae (fast black bean), red bean (red bean), mung bean, yellow bean (medium bean), and pea 1 kg is most preferred.

In addition, according to the present invention, unlike the above-mentioned portable diet substitutes, the complex nutrition broth as the present invention set includes (a) 13 kinds of vegetables, 4 kinds of fruits, 5 kinds of fish and shellfish, salt, bottled water and fishy removal and organic ingredients. Preparing alcohol as an extractant; (b) cleaning and washing the prepared 22 kinds of ingredients; (c) extracting the washed food ingredients into a super-pressure extractor with salt, bottled water and alcohol for 1 to 2 hours; (e) When the temperature of the broth juice from which the residue is removed in the above step reaches 70 ~ 80 ℃, 150mL bottled 100mL in a glass bottle and vacuum packaging.

The complex nutrition broth (soup) of the present invention prepared through the above steps has a calorie of 450 to 500 kcal and is fed with energy of 1350 to 1500 kcal when ingested three times a day for adults. The most preferable vegetables for supplying the calories are 1kg each of cabbage, carrot, burdock, radish, buttercup, green pepper, tomato, broccoli, paprika, onion, leek, garlic and ginger and 1kg each of apple, pear, grape and strawberry As the fish and shellfish, 0.5kg of salt, 100kg of mineral water, and 5kg of oysters are most preferred for 3kg of octopus, yellow, mussels, abalone and kelp.

As described above, according to the present invention, there is an effect of providing a portable simple substitute and a method for preparing the same, which is useful for one-day ingestion without toxicity, and has the effect of preventing and improving metabolic diseases such as hyperlipidemia, hypertension, diabetes, and obesity. It is also an excellent way to provide diet foods for treating patients with metabolic diseases.

1 is a diagram illustrating a manufacturing process of the present invention.
Figure 2 is a semi-finished product (a) of the dried state before tableting of the final diet substitution formula of the present invention and the soup solution for antidote (b) is a test.
Figure 3 is a figure showing the fat accumulation inhibitory effect of the present invention.
Figure 4 is a photograph showing the effect of inhibiting C / EBPa expression of the present invention.

The present invention is manufactured according to the manufacturing process sequence shown in FIG.

Specific embodiments for carrying out the present invention will be clearly described according to the embodiment, and the specific effects of the intermediate pictures (a) and (b) of the present invention will be apparent according to the experimental examples.

Dietary Meal Replacement Tablets

Preparation Balanced diet meal replacement ingredients and compounding ratios that can be operated by one adult human body is shown in Table 1 below.

Ingredient blending ratio Kinds number Ingredient Name Addition amount (kg) Remarks
Grain (A) One Waxy Brown Rice One 2 Waxy rice One 3 Millet rice One 4 Seosuk Rice One 5 Rice One 6 Whole wheat One 7 oat One system 7 kinds 7
Beans (B) 8 Seomoktae
(Rat eyes) One 9 Seo-tae
(Black Soybean) One 10 Red Beans One 11 green gram One 12 Yellow beans One 13 pea One system 6 types 6 sum 13 kinds 13

Hereinafter, the present invention will be described in detail.

After washing the ingredients of Table 1, the adult one-time meal replacement tablets were prepared through a process consisting of the following steps. Weigh 7kg and 6kg of 7 grains and 6 kinds of legumes, and add them to the cooker, and then cook them until complete.

Steamed grains and six kinds of soybeans obtained in the above step were far-infrared dried for 10 to 20 minutes until the moisture content was 10 to 15% at 130 to 150 ° C.

The dried 7 kinds of grains and 6 kinds of beans obtained in the above step were powdered using a ball miller, respectively, to form fine particles of 250 to 300 mesh.

The seven kinds of grain powder and six kinds of powdered soybean powder obtained in the above steps are transferred to a separately installed mixer, and each of the rehydrated cereals and legume dough is sprayed with distilled water with a water content of 12 to 14%. Prepared.

Each grain dough and legume dough obtained in the above step was transferred to a conveyor (Conveyor) and put into a conventional granulator to produce a granular food. In order to facilitate granulation as an edible additive in the granule manufacturing step, polydextrose was added within 2 to 3% of the total weight of each dough.

The granular foods obtained in the granulating step were re-dried for 50 to 60 minutes at a setting temperature of 100 to 105 ° C based on 10% moisture content.

Tableting the re-dried granular food with a tableting machine to put 70 tablets (70g) of 100g tablets in a 1g unit tablet sealed and vacuum-packed with aluminum bottle cap 450 ~ 1 adult once A meal replacement was prepared to supply 500 kcal energy (FIG. 2A).

Preparation of Complex Nutritional Broths

The tableting product obtained in Example 1 of the present invention is a substitute food of less than 10% of water content, so that the complex nutritional detox broth (true country) which is easy to carry along with the substitute food and drink at the same time as the adult one-time meal meal Prepared as (FIG. 2B).

The ingredients of the balanced complex detoxification broth that the adult human body of the present invention can operate are shown in Table 2 below.

Ingredient ingredient ratio for soup soup Kinds number Ingredient Name Addition amount (kg) Remarks
Vegetables
(A) One cabbage One 2 carrot One 3 burdock One 4 radish One 5 Buttercup One 6 Green pepper One 7 tomato One 8 broccoli One 9 paprika One 10 onion One 11 Green Onion One 12 garlic One 13 ginger One system 13 kinds 13
Fruits
(B) One Apple One 2 ship One 3 grape One 4 Strawberry One system 4 types 4
Seafood
(C) One octopus 3 2 Emperor 3 3 mussel 3 4 abalone 3 5 Kelp 3 system 5 types 15 Sum 22 types 32
additive One Salt 0.5 2 Jeongjong (alcohol) 5.5 3 bottled water 100 sum 138

Each of the ingredients in Table 2 was well groomed and washed, and then put into an ultra-high pressure extractor to prepare the present invention portable complex nutrition detox soup. At this time, in order to increase the extraction content of the active ingredient of the ingredients added and to enhance the flavor and taste of the soup, alcohol-containing saengjong is added to the ultra-high pressure extractor in 100L of water with salt and 500 ~ 900MPa, most preferably Was performed at 550 to 850 MPa, more preferably at 600 to 800 MPa, for 0.5 to 3 hours, preferably for 1 to 2 hours, and most preferably for 1.5 hours. Through the ultra-high pressure treatment it is advantageous to be able to extract all the ingredients effective in the human body contained in the epidermal cell wall of fish and shellfish, fruits.

The ultra-high pressure food mixture was extracted and filtered to obtain about 160 kg of the filtrate, and the residue (waste) was discarded (at this time, the waste was separately dried and used as a feed additive for compost or cattle and pigs. ).

Into the cool down extraction broth obtained in the step (70) to 80 ℃ in a glass bottle of 100mL from the extract (extract tank) by vacuum packing a one-time meal replacement broth for adults and easy to carry the present invention The soup was prepared. The calorie content of the soup of the present invention was calculated to be 4.5-5.0 kcal / mL.

Hereinafter, the working effect of the set product of the present invention will be described as an experimental example. The nutritional effect of the tableting product according to the present invention was used as it is or 70% ethanol organic solvent extraction for convenience of experiment evaluation and used as a sample of the following experimental examples.

Experimental Example 1: Cholesterol inhibitory effect of the present invention product

As a positive control group, HFCD 50% (w / w) ingested a conventional high fat diet (HFCD, high fat and colesterol diet) in a rabbit having a weight of 1 kg of the substitution formula according to the first embodiment of the present invention After 3 weeks, 6 weeks, and 12 weeks of experiments, the experimental group I fed the mixed sample, the experimental group II fed only the general feed, and the negative control group III fed the sample of the present invention, respectively, and performed the breeding experiment for 6 weeks. Blood cholesterol concentrations collected at each time point and blood cholesterol concentration were measured using a lipid automated analyzer (RA-XT, Technicon, USA). As a result, the blood cholesterol lowering effect of blood cholesterol was significantly reduced in the rabbit negative control group fed the set product of the present invention. Appeared (Table 3). In this experiment, the negative water (water) except for the negative control, the same amount of normal tap water was supplied to all the experimental groups and the experiment was performed.

Changes in Serum Cholesterol Concentration of Feed Intake (mg / dL) Breeding period Changes over time 3 6 9 12 Positive control group 68.2 ± 8.21 74.9 ± 3.32 81.4 ± 5.25 88.4 ± 3.48 Experimental group 71.4 ± 10.2 75.8 ± 9.24 79.54 ± 8.21 84.2 ± 5.79 Experimental group 65.4 ± 9.24 73.2 ± 2.55 75.22 ± 3.29 78.4 ± 3.24 Negative Control 60.2 ± 3.24 50.2 ± 3.29 47.2 ± 9.94 42.3 ± 2.22

Experimental Example 2 Analysis of Antioxidant Activity of the Set Product of the Present Invention

Antioxidant activity of the surrogate and soup soup set according to the present invention was measured and evaluated the total phenol content and total flavonoid content. The content of total phenolic compounds was measured using the Folin-Denis method. Substituted purified samples were pulverized, suspended in 70% alcohol, stirred at 4 ° C. for 24 hours, centrifuged at 13,000 g for 10 minutes, and the supernatant was used as analytical sample. Standard materials were added and mixed with 0.2 mL of coffee acid (sigma-aldrich, USA) and left for 3 minutes at room temperature. And 0.4% of saturated solution of 10% Na ₂ CO ₃ (Daejung, Korea) was added and mixed, 1.4mL of distilled water was added and reacted at room temperature for 1 hour, and then the absorbance of the supernatant was measured at 700mm. Total flavonoids were mixed by adding 0.5 mL of 10% aluminum nitrate (Sigma-Aldrich / USA), 0.1 mL of 1M Potassium acetate (Sigma-Aldrich co.), And 4.3 mL of 80% ethanol in order to 0.5 mL of sample according to the method of Moreno. After standing at room temperature for 40 minutes, absorbance was measured at 415 nm. The standard material was prepared at a concentration of 0-100 mg / mL of quercetin (Sigma-Aldrich co.) Water and analyzed in the same manner as the sample, and the total flavonoid content was calculated from the standard calibration curve.

The results of the analysis of the surrogate dietary product and soup for soup according to the present invention were as Table 4. This showed a remarkably high antioxidant effect of more than 5 times compared to the antioxidant effect of a known single product such as ordinary grains or shiitake mushrooms.

Antioxidant Effect of the Product of the Present Invention division Rule Shiitake mushrooms Invention Tablet substitute Soup Total phenolic content 15 32 78 165 Total flavonoids 12 21 75 125

Experimental Example 3 Cytotoxicity Test

Toxicity Experiments were performed on tablet substitutes and detoxification soups prepared according to Examples 1 and 2 above. The cell number was obtained by incubating RAW 264.7 (macropharge (mouse) cell line in ATCC. The cell line was used for 10% FBS (GIBCO) and 1% Penicillin-streptomycia in a 5% CO _2, 95% humidity and 37 ° C incubator. Culture was performed using a 75cm ² T-flask containing BMEM medium (GIBCO) containing (GIBCO).

The cultured cells were given to the experiment through subculture every two or three days. The RAW 264.7 cell count was measured in hemocytometer after making a single cell.

Cytotoxicity of the present product was confirmed by MTT assay using the RAW 264.7 cells the cell viability (cell viability,%).

The cytotoxicity of the present product was confirmed to be safe since all showed no concentration up to 100 mg / mL.

Experimental Example 4 Safety Test

Heavy metal and contaminated microbial tests of tablet substitutes and soups prepared according to the present invention were performed. The test results are shown in Table 5. Heavy metals were tested for lead (pb) and cadmium (cd), microorganisms were tested for normal bacteria and E. coli. Traces of ppm were detected but there was no problem with food safety.

Safety inspection of the product of the present invention number Test / inspection item Test and inspection result One pb (mg / kg) 0.028 2 cd (mg / kg) 0.024 3 General bacteria count (cfu / kg) 720 4 E. coli 0

Experimental Example 5 sensory test of the present invention

The present inventors carried out a sensory test in consideration of the fact that even if the processed foods are excellent in taste, flavor, etc., the value as a food is reduced.

Sensory test methods and experimental results are as follows.

The prepared tablet substitute and detoxification soup were randomly sampled from 50 adults and subjected to sensory evaluation by five-point scale method. The subjects of the survey were selected based on the adults who thought they were obese or who needed a diet, and the standard weight loss rate, appearance, color, and flavor after one month after providing the prototype of the present invention. scores are divided into flavor, taste, and overall acceptability. Very good 5, Good 4, Normal 3, Bad 2, Very bad 1 and the standard weight is 100 Calculated by subtracting and multiplying by 0.9.

Statistical analysis of this experiment was performed using the Spss version 18.0 program (SPSS Inc., Chicago, IL, USA), and the mean value of the overall weight change rate (Mean, m) and standard deviation (SD) were calculated. In addition, the paired-t-test was carried out for the difference in the change in the satisfaction level and the change in the weight change before and after experiencing the present invention. The general details of the surveyed panel are shown in Table 6.

General information of panel division frequency(%) division frequency(%) gender male 25 (50.0) age 20-29 22 (44.0) 30-39 19 (38.0) female 25 (50.0) 40-49 9 (18.0)

As a result of the experiment, the weight loss effect after the experience of the present invention is shown in Table 7. There was an average weight loss effect of 5.24 ± 3.21kg after the trial, and the t value was 15.12. The weight before and after the trial showed a statistically significant difference at the P <0.001 level, indicating a very useful diet product.

Weight loss effect after the present invention product experience Weight loss (kg) M ± SD t order 5.24 ± 3.21 15.12

In addition, the weight change rate is shown in Table 8. In other words, the weight loss effect was at least 4% and at most 15.2%, and the average value of the weight change rate was 9.24 ± 3.25, indicating a weight loss of 6% or more.

Weight change rate after experiencing the present invention Minimum Maximum value M ± SD % Change in weight 4.0 15.2% 9.24 ± 3.25

The difference in the satisfaction of their weight before and after the present invention experience the average increase of 2.30 ± 1.24 and the t value of 10.24 as shown in Table 9, the satisfaction of their weight after the product experience was very high.

Satisfaction with weight loss after experiencing the present invention Weight loss satisfaction M ± SD t order 2.30 ± 1.24 10.24 ^*

* P <0.001

The score above is 1 (very dissatisfied) to 5 (very satisfied).

Moreover, the result of the satisfaction survey of the product was as Table 10. 99% were satisfied with intestinal comfort and digestibility, and 100% were satisfied with aroma, taste, and overall preference.

Product Satisfaction of the Invention division Intestinal comfort and digestibility (%) Taste, Flavor, Other (%) very good 25 (45.0) 15 (29.0) Satisfaction 26 (53.0) 37 (71.0) usually 1 (2.0) 0 (0.0) dissatisfaction 0 (0.0) 0 (0.0) Very dissatisfied 0 (0.0) 0 (0.0)

Experimental Example 6 Prevention and Improvement of Metabolic Diseases

Prevention of any one or more metabolic diseases selected from obesity, diabetes, hypertension, stroke, hyperlipidemia, arteriosclerosis, or cardiovascular diseases by reducing the expression of transcription factor C / EBPa expressed in fat accumulation and adipocyte differentiation and An experiment was conducted to determine whether there was an improvement effect.

Test Method 1. Measurement of fat accumulation inhibitory effect of the present invention set product

In this Experimental Example, after the differentiation of fat progenitor cells to analyze the fat accumulation inhibitory effect of the set product of the present invention, Oil Red O staining (K Tobe et al, FEBS lett, 215 (2): 345-9, 1987).

In order to evaluate the effects on the differentiation and growth of adipocytes by the set food of the present invention, seed cells of 3T3-L1 (ATCC), which are adipocytes, were seeded on a 24-well plate ( seeded, 37 ° C, 10 using Dulbecco-modified Eagle medium (DMEM) medium supplemented with 10 ml / L of 10% Bovine Calf Serum (BCS) and antibiotic-antimycotic Cultures were grown in a confluent state in a% CO 2 incubator (Forma Scientific Co, Marjetta, OH, USA).

Confluent and grown 3T3-L1 cells in DMEM medium containing 1% antibiotic-antimycotic, 10% Fetal bovineserum (MDI) isobutyl-methylxanthine 05 mM , Differentiated adipocytes by culturing for 2 days in a culture medium containing 1 μM of dexamethasone and 5 μg / ml of insulin

(differentiation adipocytes), and then mature for two more days in DMEM medium containing 5 μg / ml insulin in DMEM medium containing 1% antibiotic-antimycotic, 10% fetal bovineserum. Differentiation into cells (mature adipocytes).

Afterwards, the cells were replaced with DMEM medium containing only 1% antibiotic-antimycotic, 10% fetal bovine serum, and cultured for two more days to form fully differentiated adipocytes.

The set product of the present invention was treated at 5, 10, 20 μM concentrations in culture at two-day intervals from the first day of differentiation by adding MDI to 3T3-L1 cells. The set product of the present invention was used by dissolving in DMSO, and cultured for a total of 6 days to remove the culture medium at the time of differentiation was completed, and stained fat cells contained in the differentiated adipocytes. To this end, 500 μl of 35% formaldehyde was suctioned for 5 minutes and fixed for 15 minutes. Then, washed three times with PBS, oil Red O solution (Oil Red O solution) was added and stained for 15 minutes. After 15 minutes, the solution was removed, washed four times with PBS, dissolved in 500 μl of isopropanol (2-propanol) and the absorbance (Optical Density, OD) value measured at 515 nm. .

Experimental results, it can be seen that the concentration of intracellular fat accumulation decreases due to the present invention set food treatment (Fig. 3), when compared to the treatment with Genistin at 80 μM concentration, the set product of the invention 4 times lower It was confirmed that the efficacy similar to the treatment with 20 μM concentration.

Experimental Method 2. Measurement of Inhibitory Effect of C / EBPa Expression of Set Product of the Present Invention

The process of differentiation into stem cells from stem cells, the first stage cells of our body, is largely divided into commitment, mitotic clonal expansion, and terminal differentiation. In the stem cells, when the cells are subjected to a commitment, they become preadipocytes, which increase the number of cells through mitotic clonal expansion, and then the terminal differential (Terminal Patent 10-1716801 Differentiation). Terminal Differentiation is the process by which differentiated adipocytes increase the amount of fat in the cell, a key transcription factor that facilitates this process. / EBPα (CCAAT / enhancer-binding proteinα)

There is PPARγ (Peroxisome proliferator-activated receptorγ) (ED Rosen et al, Mol Cell, 4 (4): 611-7,1999) C / EBPa and PPARγ are cross-regulated to allow fat progenitor cells to become fat. Regulate differentiation into cells (Z Wu et al, Mol Cell, 3 (2): 151-8, 1999). During the differentiation process, fat cells receive fatty acids through their receptors for lipogenesis. Therefore, it is known that preventing fat precursor cells from differentiating into fat cells reduces FAS (Fatty acid synthase) involved in fat synthesis. Therefore, in this experiment, Western blotting was performed to examine the effect of the present invention on the expression of C / EBPa, one of the important transcription factors that promote the process of increasing the amount of fat in the differentiated adipocytes. Western Blotting (BL Upham et al, Carcinogenesis 18: 37-42, 1997) was performed.

The 3T3-L1 cells, adipose progenitor cells, were concentrated in DMEM medium containing 10 ml Fetal Bovine Serum (FBS) and 10 ml / L of antibiotic-antimycotic. After treatment, each was incubated for 6 days. In order to extract proteins from the cultured cells were extracted with 'RIPA buffer (Cell signaling, Beverly, MA)'. Protein content was determined using a 'DC assay kit (Bio-Rad Corp, Richmond, CA, USA)'. About 50 μg of protein was extracted from each protein extract by electrophoresis in '10% SDS-PAGE '.

After each reaction using C / EBPa (Cell Signaling, Beverly, MA), the reaction was detected using an ECL kit (Amersham, Life Science, Denver, USA).

As a result, it was confirmed that the expression inhibitory effect of the transcription factor C / EBPa by the present invention set product (FIG. 4).

Claims (4)

In the manufacturing method of meal replacement meal mainly a grain and a bean;
13 kinds including 6 kinds of cereals consisting of brown rice, waxy rice, millet rice, Seosuk rice, waxy rice, whole wheat and oat The mixture of ingredients in the same weight ratio (w / w) is added to the mixture, and dried at 130 ~ 150 ℃ until the water content is 10 ~ 15%, and then powdered to 250 ~ 300 mesh size and sprayed with distilled water again. A tableting product prepared by obtaining a dough with a content of 12-14% and then formulating it into granular food and then redrying it at 100-105 ° C. to reach a water content of 10%;
Equivalent to 13 kinds of vegetables consisting of cabbage, carrot, burdock, radish, buttercup, green pepper, tomato, broccoli, paprika, onion, leek, garlic and ginger and 4 kinds of fruits consisting of apple, pear, grape and strawberry Of 5 kinds of fish and shellfish consisting of octopus, yellow, mussels, abalone and kelp, and then mixed in the same weight ratio (w / w). Easy-to-use adult diet substitute consisting of detoxification soup made from 550-850 MPa of ultra-high pressure extraction at 550-850 MPa for 1-2 hours to produce 4.5-5.0 kcal / mL calories. The tableting product of the surrogate diet for adult diet consists of a glass bottle and 70 mL of 70 g tablets in 1 g unit and a 100 mL glass bottle for detoxifying soup and vacuum packaging and a 150 mL glass bottle for adults. An easy to carry substitute diet for adults, characterized by the ability to supply 1,000 kcal. delete The substitute formula of claim 2 consists of tableting product 70g / 450 ~ 500kcal and detoxification soup 100mL / 450 ~ 500kcal and 100mL and 150mL respectively, characterized in that the vacuum packaging in a glass bottle for a portable adult diet substitute.

Images